Truist Securities analyst Joon Lee reiterated a Buy rating on Catalyst Pharmaceutical Partners (NASDAQ: CPRX), following the company's prelim Q4 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE